Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial
Régis Peffault de Latour, Jeff Szer, Ilene C. Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, Kensuke Usuki, Morag Griffin, Jean‐Jacques Kiladjian, Carlos M. de Castro, Hisakazu Nishimori, Temitayo Ajayi, Mohammed Al-Adhami, Pascal Deschatelets, Cedric Francois, F Grossi, Antonio M. Risitano, Peter Hillmen
Topics & Concepts
MedicineEculizumabClinical endpointInternal medicineRegimenOpen labelClinical trialRandomized controlled trialAntibodyImmunologyComplement systemComplement system in diseasesBlood groups and transfusionPlatelet Disorders and Treatments